ABSTRACT

The drug rufinamide was approved in November 2008 by the US Food and Drug Administration for use in the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients older than 4 years. Lennox-Gastaut Syndrome is one of the most treatment-resistant epilepsies, and seizures require a diversity of polytherapy. In recent years, a remarkable number of reports have been published on the effectiveness of rufinamide in childhood epileptic encephalopathy and epileptic spasms, tonic seizures, myoclonic-astatic epilepsy, Dravet syndrome, and refractory partial seizures dependent on migration abnormalities. This article discusses the efficiency of rufinamide as used in the treatment of five refractor epileptic cases at the Epilepsy Clinic established in Antalya Education and Research Hospital in August 2011.

Keywords: Dirençli epilepsi, Lennox-Gastaut sendromu, rufinamid, subakut sklerozan panensefalit